INTS Company Profile and Key Details

NASDAQ : INTS

Intensity Therapeutics

$0.41

0.0346+9.21%

At Close 4:00 PM

60.4

ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Intensity Therapeutics, Inc. (INTS) stock surged +9.21%, trading at $0.41 on NASDAQ, up from the previous close of $0.38. The stock opened at $0.37, fluctuating between $0.37 and $0.41 in the recent session.

Stock Snapshot

0.3756

Prev. Close

19.34M

Market Cap

0.37

Day Low

-0.75

P/E Ratio

-0.55

EPS (TTM)

-0.53

Cash Flow per Share

0.37

Open

47.15M

Number of Shares

0.413

Day High

53.88%

Free Float in %

0.96

Book Value

1.53M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 31, 2025	0.37	0.41	0.37	0.41	1.53M
Dec 30, 2025	0.37	0.38	0.35	0.38	2.18M
Dec 29, 2025	0.40	0.40	0.37	0.37	1.66M
Dec 26, 2025	0.41	0.41	0.39	0.39	712.97K
Dec 24, 2025	0.41	0.42	0.40	0.41	345.33K
Dec 23, 2025	0.41	0.42	0.37	0.42	1.89M
Dec 22, 2025	0.42	0.43	0.41	0.42	1.08M
Dec 19, 2025	0.40	0.43	0.40	0.41	797.17K
Dec 17, 2025	0.46	0.46	0.42	0.42	2.08M
Dec 16, 2025	0.41	0.45	0.40	0.44	2.17M
Dec 15, 2025	0.46	0.46	0.41	0.42	2.02M
Dec 12, 2025	0.60	0.60	0.42	0.47	6.61M
Dec 11, 2025	0.57	0.60	0.56	0.59	3.9M
Dec 10, 2025	0.53	0.57	0.50	0.55	4.19M
Dec 09, 2025	0.49	0.53	0.48	0.53	1.91M
Dec 08, 2025	0.54	0.54	0.46	0.50	4.91M
Dec 05, 2025	0.49	0.53	0.48	0.51	8.19M
Dec 04, 2025	0.44	0.49	0.40	0.46	13.59M
Dec 03, 2025	0.36	0.42	0.36	0.41	1.97M
Dec 02, 2025	0.37	0.39	0.35	0.36	1.55M

Contact Details

Westport, CT 06880

United States

https://www.intensitytherapeutics.com 203 221 7381

About Company

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Stock Peers

ARGX

3.05+0.36%

argenx SE$840.95 REGN

-2.07-0.27%

Regeneron Pharmaceuticals, Inc.$771.87 MDGL

-1.39-0.24%

Madrigal Pharmaceuticals, Inc.$582.34 UTHR

-8.94-1.80%

United Therapeutics Corporation$487.25 VRTX

-0.38-0.08%

Vertex Pharmaceuticals Incorporated$453.36 ALNY

0.4+0.10%

Alnylam Pharmaceuticals, Inc.$397.65 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-2.28-0.77%

Praxis Precision Medicines, Inc.$294.74 KRYS

-1.34-0.54%

Krystal Biotech, Inc.$246.54 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Intensity Therapeutics, Inc. (NASDAQ:INTS) closed at $0.41 USD, gaining $0.03 (9.21%) from the previous close of $0.38. The stock is currently mid-range between its 52-week high and low $0.18 and $3.17. With a market capitalization of about $19.34 million, Intensity Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~4.24). Key stats such as the average daily volume over the past year has been around 30.73 million shares, volume is running light vs its 52-week average. Headquartered in Westport, CT, Intensity Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Lewis H. Bender, the company employs approximately 5 people and listed since June 30, 2023. Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -8.01%, SMA50 -6.82%, SMA200 -28.85%). The stock’s 14-day RSI is 48.08 (neutral), while the ATR of 0.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -87.04% below its high and over 121.37% above its low. Average 10-day trading volume of 1.34 million shares is below the 3-month average of 28.95 million, indicating normal recent market interest.

Valuation Metrics

Intensity Therapeutics, Inc. trades at a P/E ratio of -1.48, slightly below the S&P 500 average, with a price-to-sales ratio of 790.92 and a price-to-book ratio of 2.4 suggesting the stock is closer to book value. The P/FCF stands at -2.0, also above market averages.

Dividend & Fair Value

Intensity Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.18. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Intensity Therapeutics, Inc. generated EPS of -$0.63 over the past year. Five-year average earnings growth is -23.29%. Wall Street analysts project EPS growth of 40.02% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $8.50 to $1.50. The high target offers 1973.17% upside. The low target suggests 265.85% downside. The mean target is $4.33. This offers 956.1% upside. Intensity Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 0.0%. The prior quarter beat by 116.67%. Over the last six quarters, Apple has recorded several small beats. These include 12.5% in August 08, 2024.

Shareholding & Insider Activity

Intensity Therapeutics, Inc. has 47.06 million shares outstanding. The public float is 40.82 million shares, elevated short interest at 2.32% of float. This equals 945.06 thousand shares. The short ratio is 0.18 days. Institutional investors hold 7.92% of the float. Insiders own 13.25%.

Financial & Profitability Overview

Over the trailing twelve months, Intensity Therapeutics has not generated any revenue. Returns are negative, with ROA at -60.93% and ROE at -80.06%.
On valuation metrics, Intensity Therapeutics trades at a P/E of -1.48, P/S of 790.92 and P/B of 2.40. The current ratio is 3.60 and quick ratio is 3.60. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -24586.40 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -80.51.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Intensity Therapeutics posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $147.00K (margin 0.00%). Operating income was - $8.32M (margin 0.0%). Net income was- $10.54M (EPS - $1.22).
The company ended the quarter with $14.78M in cash and short-term investments, a total debt of $158.00K, and net debt of - $8.40M. Total assets were $17.30M, with equity of $13.16M. Financials further reflected weakness, with operating cash flow of - $7.21M, free cash flow of - $7.21M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Intensity Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -7.36%, with price expected at $0.38 by January 13, 2026, within a range of $0.31 to $0.44 3-Month Outlook: Projected rise of 272.99%, reaching $1.53 by March 30, 2026, with a range of $1.44 to $1.61. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by December 30, 2026, within a range of $0.00 to $0.14.

Key Takeaways

Intensity Therapeutics, Inc. (NASDAQ:INTS) shares are down -76.69% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Intensity Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.48. Analyst sentiment is cautious, with the majority of ratings in Speculative Buy territory and a mean price target of $6.00, suggesting 1362.7% upside. Our AI forecast model points to short-term weakness (-7.36% over two weeks), a medium-term rise (272.99% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Intensity Therapeutics, Inc. (INTS) stock price?

Intensity Therapeutics, Inc. (NASDAQ: INTS) stock price is $0.41 in the last trading session. During the trading session, INTS stock reached the peak price of $0.41 while $0.37 was the lowest point it dropped to. The percentage change in INTS stock occurred in the recent session was 9.21% while the dollar amount for the price change in INTS stock was $0.03.

INTS's industry and sector of operation?

The NASDAQ listed INTS is part of Biotechnology industry that operates in the broader Healthcare sector. Intensity Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of INTS?

No Data

How INTS did perform over past 52-week?

INTS's closing price is 121.73% higher than its 52-week low of $0.19 where as its distance from 52-week high of $3.17 is -87.04%.

How many employees does INTS have?

Number of INTS employees currently stands at 5.

Link for INTS official website?

Official Website of INTS is: https://www.intensitytherapeutics.com

How do I contact INTS?

INTS could be contacted at phone 203 221 7381 and can also be accessed through its website. INTS operates from 61 Wilton Road, Westport, CT 06880, United States.

How many shares of INTS are traded daily?

INTS stock volume for the day was 1.53M shares. The average number of INTS shares traded daily for last 3 months was 30.73M.

What is the market cap of INTS currently?

The market value of INTS currently stands at $19.34M with its latest stock price at $0.41 and 47.15M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	5
Beta	4.24
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

INTS Company Profile and Key Details

Intensity Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook